Brought to you by 
J&J gets rights to MGI Pharma's Dacogen for MDS
Jul 2006
Executive Summary
Johnson & Johnson's Janssen-Cilag companies have been granted exclusive worldwide (excluding North America) development and marketing rights to MGI Pharma's Dacogen (decitabine). The methylase inhibitor is injected into patients with myelodysplastic syndromes (MDS; bone marrow disorders).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J gets rights to MGI Pharma's Dacogen for MDS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice